TABLE 3.

Univariate and Multivariate Analysis of Recurrence-free Survival

	Univariate Analysis		Multivariate Analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (yr)
<65	1.13 (0.83–1.54)	0.44
≥65	1
Sex
Male	1.01 (0.65–1.57)	0.95
Female	1
Location
Ut	1	0.97
Mt/Lt	1.01 (0.69–1.47)
Histological differentiation (SCC)
Well/mod	1
Poor	1.21 (0.77–1.92)	0.41
NAC regimen
ACF	1.04 (0.75–1.43)	0.83
DCF	1
ypT
0–2	1	<0.001	1	0.005
3–4	2.20 (1.62–2.99)		1.65 (1.16–2.33)
ypN
0–1	1	<0.001	1	0.004
2–3	2.62 (1.94–3.54)		1.62 (1.16–2.26)
Clinical response of PT∗
Responders	1	0.006	1	0.54
Nonresponders	1.55 (1.14–2.11)		1.11 (0.79–1.56)
Pathological PT regression grade†
Responders	1	<0.001	1	0.67
Nonresponders	2.12 (1.40–3.23)		1.10 (0.69–1.76)
Total LN regression grade†
Responders	1	<0.001	1	<0.001
Nonresponders	3.04 (2.20–4.20)		2.25 (1.56–3.24)

^∗Responder was defined as complete or partial response, and nonresponder as stable or progressive disease.

^†Responder was defined as grade III and IV, and nonresponder as grade I and II.

ACF indicates adriamycin, cisplatin, and 5-fluorouracil; CI, confidence interval; DCF, docetaxel, cisplatin, and 5-fluorouracil; HR, hazard ratio; LN, lymph node; Lt, lower thorax including esophagogastric junction; Mt, middle thorax; NAC, neoadjuvant chemotherapy; PT, primary tumor; SCC, squamous cell carcinoma; Ut, upper thorax.